TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.
Brief Summary: It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil SR 23 mg) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil IR 10 mg) | Intervention Type: DRUG; Name: Aricept (donepezil SR 23 mg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aricept (donepezil IR 10 mg); Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: SB-742457; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.
Brief Summary: It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.


Options:
A: Arm Label: Galantamine and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Galantamine CR, Drug: Placebo | Arm Label: Galantamine and Memantine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine CR, Drug: Memantine | Intervention Type: DRUG; Name: Galantamine CR; Assigned to Arm(s): Galantamine and Memantine, Galantamine and Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Galantamine and Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Galantamine and Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Expanded Prenatal Testing Options and Informed Choice
Brief Summary: The proposed study will determine the impact of providing complete information about all prenatal tests for chromosomal disorders to racially/ethnically and sociodemographically diverse women of all ages and allowing them to make informed choices regarding which tests - if any - to undergo. Specifically, we propose to update a validated prenatal testing decision-assisting tool ("PT Tool") to incorporate new screening options and make it more accessible to lower literacy and culturally diverse populations. We then will conduct a randomized controlled trial comparing the effect of an "informed free choice" approach consisting of providing complete information regarding and access to all prenatal testing options to that of usual care among a diverse population of pregnant women.


Options:
A: Arm Label: Computerized decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Informed free choice | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Informed free choice; Assigned to Arm(s): Computerized decision aid
B: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
C: Arm Label: FOBT by laboratory requisition or directly by PCP; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FOBT by lab req. or directly from PCP + study magnet; Type: EXPERIMENTAL; Interventions: Behavioral: Refrigerator Magnet | Intervention Type: BEHAVIORAL; Name: Refrigerator Magnet; Assigned to Arm(s): FOBT by lab req. or directly from PCP + study magnet
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: CHOICE decision aid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: YourMeds patient education program | Intervention Type: BEHAVIORAL; Name: CHOICE decision aid; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: YourMeds patient education program; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis
Brief Summary: The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.


Options:
A: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily
B: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo
C: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)
D: Arm Label: Increase mesalamine dose by 2.4g/day; Type: EXPERIMENTAL; Interventions: Drug: mesalamine | Arm Label: Maintain mesalmine dose; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): Increase mesalamine dose by 2.4g/day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium
Brief Summary: The purpose of the study is to determine whether dexmedetomidine is a more effective medication than haloperidol in the treatment of agitation and delirium in patients receiving mechanical ventilation in an intensive care unit. Haloperidol is a medication conventionally used for this purpose.

The investigators will study only patients who have recovered from their illness to the point that, were it not for agitation and delirium, they would no longer require mechanical ventilation.

The investigators hypothesize that patients receiving dexmedetomidine will be able to discontinue mechanical ventilation earlier than those receiving haloperidol.


Options:
A: Arm Label: Haloperidol Eligible Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reduced exposure to anticholinergics, Procedure: Reduced exposure to benzodiazepines, Drug: Haloperidol | Arm Label: Haloperidol Eligible Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Haldol-Ineligible Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Reduced exposure to anticholinergics, Procedure: Reduced exposure to benzodiazepines | Arm Label: Haldol Ineligible Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Intervention Type: BEHAVIORAL; Name: Reduced exposure to anticholinergics; Assigned to Arm(s): Haldol-Ineligible Arm, Haloperidol Eligible Intervention | Intervention Type: PROCEDURE; Name: Reduced exposure to benzodiazepines; Assigned to Arm(s): Haldol-Ineligible Arm, Haloperidol Eligible Intervention | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol Eligible Intervention | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Haldol Ineligible Usual Care, Haloperidol Eligible Usual Care
B: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
C: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium
Brief Summary: The purpose of the study is to determine whether dexmedetomidine is a more effective medication than haloperidol in the treatment of agitation and delirium in patients receiving mechanical ventilation in an intensive care unit. Haloperidol is a medication conventionally used for this purpose.

The investigators will study only patients who have recovered from their illness to the point that, were it not for agitation and delirium, they would no longer require mechanical ventilation.

The investigators hypothesize that patients receiving dexmedetomidine will be able to discontinue mechanical ventilation earlier than those receiving haloperidol.


Options:
A: Arm Label: A - placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): A - placebo
B: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): haloperidol
C: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Care for Korean Americans
Brief Summary: The purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged ethnic minority immigrant populations (Korean Americans) with type 2 DM.


Options:
A: Arm Label: Usual education (standard care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensive initial education; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive initial education | Intervention Type: BEHAVIORAL; Name: Intensive initial education; Assigned to Arm(s): Intensive initial education
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Care for Korean Americans | Intervention Type: BEHAVIORAL; Name: Diabetes Care for Korean Americans; Assigned to Arm(s): 1
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity Information (DVD); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DVD | Arm Label: High Intensity Information (Promotora); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promotora | Intervention Type: BEHAVIORAL; Name: DVD; Assigned to Arm(s): Low Intensity Information (DVD) | Intervention Type: BEHAVIORAL; Name: Promotora; Assigned to Arm(s): High Intensity Information (Promotora)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
Brief Summary: This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH, Drug: OROS MPH Tablets | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo Tablets | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: OROS MPH Tablets; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 002
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System (MTS) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo patch | Intervention Type: DRUG; Name: Methylphenidate Transdermal System (MTS); Assigned to Arm(s): A | Intervention Type: OTHER; Name: placebo patch; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia
Brief Summary: This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.


Options:
A: Arm Label: PhosLo; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): PhosLo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Ferric Citrate; Type: EXPERIMENTAL; Interventions: Drug: Ferric Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ferric Citrate; Assigned to Arm(s): Ferric Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo 20mg; Type: PLACEBO_COMPARATOR; Interventions: Other: chewing gum | Arm Label: K2CG 60 mg extender; Type: ACTIVE_COMPARATOR; Interventions: Other: chewing gum | Arm Label: K2CG 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Other: chewing gum | Arm Label: K2CG 20mg extender; Type: ACTIVE_COMPARATOR; Interventions: Other: chewing gum | Arm Label: K2CG 20mg; Type: ACTIVE_COMPARATOR; Interventions: Other: chewing gum | Arm Label: Placebo 60mg; Type: PLACEBO_COMPARATOR; Interventions: Other: chewing gum | Intervention Type: OTHER; Name: chewing gum; Assigned to Arm(s): K2CG 20mg, K2CG 20mg extender, K2CG 60 mg, K2CG 60 mg extender, Placebo 20mg, Placebo 60mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MCI-196 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MCI-196; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.
Brief Summary: This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with type 2 diabetes naive to previous insulin therapy.


Options:
A: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir | Arm Label: insulin NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin NPH | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): insulin NPH
B: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
C: Arm Label: Insulin glargine injected at bedtime; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine at bedtime instead of NPH | Arm Label: NPH insulin injected twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH twice-daily | Intervention Type: DRUG; Name: Insulin glargine at bedtime instead of NPH; Assigned to Arm(s): Insulin glargine injected at bedtime | Intervention Type: DRUG; Name: NPH twice-daily; Assigned to Arm(s): NPH insulin injected twice-daily
D: Arm Label: Insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir | Arm Label: Insulin NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin NPH | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): Insulin NPH

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia
Brief Summary: This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to \< 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye. The study is a randomized clinical trial comparing intensive treatment (42 hours per week of patching plus daily atropine) with a control group that will have rapid weaning of existing treatment followed by spectacle correction only (if needed). The primary objective is to determine if this intensive treatment will improve visual acuity in patients with residual amblyopia.

The primary outcome assessment is amblyopic eye visual acuity at 10 weeks.

The primary analytic approach for the amblyopic eye acuity will be a treatment group comparison of the proportion of patients with at least two lines of visual acuity improvement.


Options:
A: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
B: Arm Label: Intensive; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Arm Label: Weaning; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Intensive | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Intensive | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Weaning | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Weaning
C: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching
D: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A

Answer: B